Regeneron Buys Tirzepatide-Like Product With Eye On Muscle-Preserving Combinations

Paying Hansoh $80m Up Front For GIP/GLP-1 Agonist

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.